Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Balstilimab by Agenus for Pleomorphic Liposarcoma: Likelihood of Approval
Balstilimab is under clinical development by Agenus and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase II...
Balstilimab by Agenus for Dedifferentiated Liposarcoma: Likelihood of Approval
Balstilimab is under clinical development by Agenus and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II...
Balstilimab by Agenus for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Balstilimab is under clinical development by Agenus and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). According to...
Botensilimab by Agenus for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...
Botensilimab by Agenus for Non-Small Cell Lung Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
AGEN-2373 by Agenus for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
AGEN-2373 is under clinical development by Agenus and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData,...
Botensilimab by Agenus for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Botensilimab by Agenus for Metastatic Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Botensilimab by Agenus for Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III...
Zalifrelimab by Agenus for Cervical Cancer: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Zalifrelimab by Agenus for Solid Tumor: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
AGEN-1571 by Agenus for Solid Tumor: Likelihood of Approval
AGEN-1571 is under clinical development by Agenus and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Zalifrelimab by Agenus for Synovial Sarcoma: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Synovial Sarcoma. According to GlobalData, Phase II...
Zalifrelimab by Agenus for Fibrosarcoma: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Fibrosarcoma. According to GlobalData, Phase II drugs...
Zalifrelimab by Agenus for Pleomorphic Liposarcoma: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase II...
Zalifrelimab by Agenus for Round Cell Liposarcoma: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Round Cell Liposarcoma. According to GlobalData, Phase...
Zalifrelimab by Agenus for Myxoid Liposarcoma: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Myxoid Liposarcoma. According to GlobalData, Phase II...
Zalifrelimab by Agenus for Dedifferentiated Liposarcoma: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II...
Zalifrelimab by Agenus for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). According to...
Balstilimab by Agenus for Squamous Cell Carcinoma: Likelihood of Approval
Balstilimab is under clinical development by Agenus and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase...